查詢結果分析
相關文獻
- 阿茲海默症藥物治療的進展
- 阿茲海默症的新展望
- Metrifonate--一種治療阿茲海默症(Alzheimer's disease, AD)的新藥
- Donepezil(Aricept[feb9])--治療阿茲海默症的新藥
- Efficiency, Capacity, and Implicit Learning: An Account of the Effects of Aging and Alzheimer's Disease on the Performance in Sequence Learning
- 失智症患者的語言表現和治療
- 阿茲海默症之新進研究與未來展望
- 阿茲海默症用乙醯膽鹼酶抑制劑治療之爭議
- 阿茲海默症的主嫌犯--類澱粉蛋白β的危害
- 預防阿茲海默症--吃出腦的健康來!
頁籤選單縮合
題 名 | 阿茲海默症藥物治療的進展=The New Evolution of Therapeutic Drugs for Alzheimer's Disease |
---|---|
作 者 | 林舒婷; 陳立偉; 林勇志; 鄧新棠; | 書刊名 | 藥學雜誌 |
卷 期 | 28:1=110 2012.03[民101.03] |
頁 次 | 頁37-41 |
分類號 | 418.21 |
關鍵詞 | 阿茲海默症; 血管張力素受體阻斷劑; 乙醯膽鹼酯酶抑制劑; Alzheimer's disease; Angiotensin receptor blocker; Acetylcholinesterase inhibitor; |
語 文 | 中文(Chinese) |
中文摘要 | 老人是一種社會資源,可以從中得知相當多的知識與歷史。但是,高齡化的社會也產生了另一種社會問題,尤其是老年失智 — 阿茲海默症。台灣老年人口的快速增加,盛行於老年人的失智症人數也隨之增加。最近的研究顯示,台灣失智症的盛行率,在65歲以上老人約為2-4%。在台灣65歲以上老人的發生率,每年每千人約有13人會變成失智老人。 目前用於治療阿茲海默症的藥品為兩大類:乙醯膽鹼酯酶抑制劑和 NMDA 受體拮抗劑。此外還有其他正在研究中的藥物,像是抗氧化藥物、抗體等。而血管張力素受體阻斷劑除了可以降血壓,減少血管性失智的發生外,也會透過其他機轉降低阿茲海默症的發生率及延緩惡化,將可成為輔助性治療的新選擇。 |
英文摘要 | The elderly, is a social resource, you can learn a lot from the knowledge and history. However, the aging society also had another social problem, particularly dementia- Alzheimer's disease. Because of Taiwan's rapidly growing elderly population, the prevalence of dementia in older people also increased. Recent studies have shown that the prevalence of dementia in Taiwan, in the elderly over age 65 is about 2-4%. More than 65 years in Taiwan, the incidence of elderly people, about 13 per thousand people per year will become elderly dementia. Currently used to treat Alzheimer's disease into two main categories of drugs are acetylcholinesterase inhibitor and NMDA receptor antagonist. In addition there are other drugs under study, such as antioxidant drugs, antibodies and so on. The angiotensin receptor blockers in addition to lowering blood pressure reduced the incidence of vascular dementia, also to reduce the incidence of Alzheimer's disease and slow deterioration by some mechanisms, which will likely become a new choice as auxiliary therapy. |
本系統中英文摘要資訊取自各篇刊載內容。